<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-32794" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Progeria</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sickles </surname>
            <given-names>Christine K.</given-names>
          </name>
          <aff>Lewis Gale Hospital Montgomery</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gross</surname>
            <given-names>Gary P.</given-names>
          </name>
          <aff>Lewis Gale Hospital Montgomery</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Christine Sickles declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gary Gross declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>11</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-32794.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Werner syndrome, also known as adult progeria, is a rare autosomal recessive condition that begins in late adolescence or early adulthood and leads to early aging. It presents with characteristic physical and metabolic abnormalities that result in severe complications more commonly seen in the elderly, including diabetes, hypertension, osteoporosis, myocardial infarction, stroke, and cancer. This activity describes the evaluation and management of patients with Werner syndrome and highlights the interprofessional team's role in improving care for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Determine&#x000a0;how to counsel a patient with Werner syndrome.</p></list-item><list-item><p>Apply&#x000a0;the evaluation of Werner syndrome.</p></list-item><list-item><p>Identify treatment options for Werner syndrome.</p></list-item><list-item><p>Communicate&#x000a0;the importance of collaboration and coordination amongst the interprofessional team in optimizing the care of patients with Werner syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=32794&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=32794">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-32794.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Werner syndrome (WS) is&#x000a0;1 of the premature aging syndromes named progeria. Otto Werner first described it in 1904. It is a rare autosomal recessive condition that begins in late adolescence or early adulthood. It presents with characteristic physical and metabolic abnormalities that result in severe age-associated complications, such as diabetes, hypertension, osteoporosis, myocardial infarction, stroke, and cancer, that are&#x000a0;normally seen in the elderly population.<xref ref-type="bibr" rid="article-32794.r1">[1]</xref><xref ref-type="bibr" rid="article-32794.r2">[2]</xref><xref ref-type="bibr" rid="article-32794.r3">[3]</xref><xref ref-type="bibr" rid="article-32794.r4">[4]</xref></p>
      </sec>
      <sec id="article-32794.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Werner syndrome is an inherited disorder that results in the loss of function in the DNA protective repair mechanisms.&#x000a0;Genetic instabilities are a normal&#x000a0;feature of aging, but the body cannot repair these abnormalities in Werner syndrome. This results in the accumulation of genetic instabilities, manifesting as a premature aging phenotype in the affected individual. Premature aging only affects certain types of tissue. Premature neurocognitive deficits are not typically seen in Werner syndrome patients, making an argument against the classification of an overall accelerated aging syndrome, but more a segmental aging syndrome.<xref ref-type="bibr" rid="article-32794.r5">[5]</xref><xref ref-type="bibr" rid="article-32794.r6">[6]</xref></p>
      </sec>
      <sec id="article-32794.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Werner syndrome is estimated to occur in 1 out of 100,000 live births worldwide. It has a high prevalence in Japan, where the frequency has been reported as high as 1 in 20,000 to 40,000 live births. The prevalence in the United States has been reported as 1 in 200,000 live births.</p>
      </sec>
      <sec id="article-32794.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Werner syndrome is caused by a truncating mutation in the <italic toggle="yes">WRN</italic> gene due to the production of a stop codon from a nonsense or frameshift mutation. The <italic toggle="yes">WRN</italic> gene encodes a 142 amino acid protein in the Rec Q DNA helicase family. Its function is to unwind the 2 DNA strands and act as an exonuclease. The <italic toggle="yes">WRN</italic> gene plays a role in maintaining proper DNA replication and repair through base excision repair, non-homologous end-joining, and homologous recombination. It also maintains telomere stability, which is pivotal for genomic stability. Telomeres are a marker for aging and act by counting the number of cell divisions. It is postulated that epigenetic changes to histones can contribute to the pathogenesis of&#x000a0;Werner syndrome, but there is not enough data to support this theory.</p>
        <p>The mechanism behind skeletal muscle loss is unknown but postulated due to a defect in the mesenchymal stem cells in patients with Werner syndrome. The stem cells are thought to have a senescent phenotype in&#x000a0;Werner syndrome, rendering a low capacity for regenerative potential.</p>
      </sec>
      <sec id="article-32794.s6" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>Caution should be exercised with Werner syndrome&#x000a0;patients and chemotherapy treatments. They are at an increased risk of chemotoxicity due to their impaired ability in DNA repair mechanisms.</p>
      </sec>
      <sec id="article-32794.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Werner syndrome patients appear unaffected at birth and develop normally until the adolescent period or second decade of life, when they start to exhibit signs and symptoms of accelerated aging. Patients develop skin ulcers, cataracts, graying or even hair loss, and hypogonadism. The loss of subcutaneous fat and dermal atrophy produce a scleroderma-like appearance. They typically have a bird-like face with short stature, high-pitched voice, dental abnormalities, decreased body weight, and body mass index (BMI).</p>
        <p>Patients also experience a rapid loss of muscle mass, most notably in the limbs, with sparing of the trunk. They also have a decrease in their grip strength and skeletal muscle index, reaching the level of sarcopenia before the age of 40. They have impaired mobility and suffer from osteoporosis of the distal limb bones, more so than the vertebral column. Soft tissue calcifications can occur, most commonly in the Achilles tendon. Pes planus, hallux valgus, and flexion contractures can occur in the feet with subsequent development of ulceration, osteitis, and osteomyelitis.</p>
        <p>Metabolic abnormalities also occur, including the development of type 2 diabetes mellitus and an increase in visceral fat accumulation. Cardiovascular abnormalities develop as well, which can include atherosclerosis, mitral regurgitation, and aortic stenosis.</p>
        <p>WS patients are at an increased risk of tumor formation, with up to 10% of patients developing a&#x000a0;malignancy. However, the types of tumors that develop are unusual compared to the aging population. Up to 50% of the malignancies reported are soft tissue sarcomas, such as schwannoma, rhabdomyosarcoma, malignant fibrous histiocytoma, leiomyosarcoma, and osteosarcoma of the upper extremities. Patients have also been reported to develop meningiomas, malignant melanoma, and thyroid carcinomas.</p>
      </sec>
      <sec id="article-32794.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Genetic testing through nuclear sequencing by reverse transcription-polymerase chain reaction (PCR) with western blot protein analysis can confirm the diagnosis of Werner syndrome. Prenatal testing with amniocentesis and chorionic villus sampling is now done in patients at high risk for having infants with this disorder.<xref ref-type="bibr" rid="article-32794.r7">[7]</xref><xref ref-type="bibr" rid="article-32794.r8">[8]</xref><xref ref-type="bibr" rid="article-32794.r5">[5]</xref><xref ref-type="bibr" rid="article-32794.r9">[9]</xref></p>
        <p>Patients diagnosed with Werner syndrome&#x000a0;should undergo regular screening tests for hyperlipidemia, breast and colorectal cancer, diabetes, and thyroid abnormalities. Given the number of musculoskeletal abnormalities and high prevalence of soft tissue sarcomas in&#x000a0;Werner syndrome&#x000a0;patients, clinicians should perform an X-ray, CT, or MRI study in the appropriate clinical&#x000a0;scenario to thoroughly evaluate for underlying disorders, infections, or tumors. DEXA scans should also be performed regularly to evaluate and monitor osteoporosis.</p>
      </sec>
      <sec id="article-32794.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of Werner syndrome&#x000a0;is aimed at symptomatic relief and control of secondary organ dysfunction. Treatment of atherosclerosis, hypertension, diabetes, and other diseases&#x000a0;is achieved through standard conventional monitoring and medical therapy, but the disorder continues to progress. It has been reported that bosentan, which is an endothelin receptor antagonist, can be used to treat severe cutaneous ulcers. Sodium etidronate can help improve symptomatic calcifications in the soft tissue. Orthotics can be used to manage complications with foot deformities. Cataracts should be managed surgically.&#x000a0;Sarcopenia can be treated with diets rich in branched amino acids, exercise, vitamin D supplementation, and hormone therapy, although this is controversial given the increased risk of malignancy.</p>
      </sec>
      <sec id="article-32794.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis includes systemic sclerosis, dermatomyositis, and other premature aging syndromes. These include Hutchinson-Gilford Progeria syndrome, Bloom syndrome, Cockayne syndrome, ataxia telangiectasia, xeroderma pigmentosum, and Wiedemann-Rauten-Strauch syndrome.&#x000a0;</p>
      </sec>
      <sec id="article-32794.s11" sec-type="Staging">
        <title>Staging</title>
        <p>If a Werner syndrome&#x000a0;patient develops a malignancy, they should be referred to the appropriate specialist for the staging of the tumor.</p>
      </sec>
      <sec id="article-32794.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Werner syndrome patients typically live into the fifth decade of life. Patients usually die of malignancy or cardiovascular disease.</p>
      </sec>
      <sec id="article-32794.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Complications are tied to the symptoms derived from affected systems as described above. Werner syndrome patients have an elevated risk&#x000a0;of developing&#x000a0;cancer, particularly skin and&#x000a0;thyroid cancers. These patients typically have shorter than average life spans, with cancer and myocardial infarction being the most common causes of death.</p>
      </sec>
      <sec id="article-32794.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>Management of Werner syndrome&#x000a0;patients should include an interdisciplinary approach based on the patient's secondary complications. This may include&#x000a0;endocrinology, dietetics, cardiology, geriatrics, ophthalmology, infectious disease, oncology, and orthopedic surgery.</p>
      </sec>
      <sec id="article-32794.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Clinicians should refer patients and their families to a genetic counselor for further information regarding the condition. They should also be encouraged to join a support group like the National Organization for Rare Disorders.</p>
      </sec>
      <sec id="article-32794.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Werner syndrome is a very rare genetic disorder, and it is unlikely that most clinicians ever see such a case. However, because the disorder involves rapid aging of the entire body, these individuals need to be seen by an interprofessional team that includes a social worker, therapist, cardiologist, dermatologist, endocrinologist, orthopedic surgeon, ophthalmologist, oncologist, and rheumatologist. The key is to improve the quality of life and provide supportive care. There is no cure for Werner&#x000a0;syndrome, and most people affected by the disorder are dead by the fifth decade of life. Thus, it is important not to offer radical surgeries and procedures because this usually leads to more harm than good.<xref ref-type="bibr" rid="article-32794.r10">[10]</xref></p>
      </sec>
      <sec id="article-32794.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=32794&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=32794">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/progeria/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=32794">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/32794/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=32794">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-32794.s18">
        <title>References</title>
        <ref id="article-32794.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarbacher</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Halper</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Connective Tissue and Age-Related Diseases.</article-title>
            <source>Subcell Biochem</source>
            <year>2019</year>
            <volume>91</volume>
            <fpage>281</fpage>
            <page-range>281-310</page-range>
            <pub-id pub-id-type="pmid">30888657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32794.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isaev</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Stelmashook</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Genrikhs</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Neurogenesis and brain aging.</article-title>
            <source>Rev Neurosci</source>
            <year>2019</year>
            <month>Jul</month>
            <day>26</day>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>573</fpage>
            <page-range>573-580</page-range>
            <pub-id pub-id-type="pmid">30763272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32794.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuk</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Alleviation of Senescence via ATM Inhibition in Accelerated Aging Models.</article-title>
            <source>Mol Cells</source>
            <year>2019</year>
            <month>Mar</month>
            <day>31</day>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>210</fpage>
            <page-range>210-217</page-range>
            <pub-id pub-id-type="pmid">30726661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32794.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sargolzaeiaval</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schleit</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lessel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kubisch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Precioso</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Sillence</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hisama</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Dorschner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Oshima</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>CTC1 mutations in a Brazilian family with progeroid features and recurrent bone fractures.</article-title>
            <source>Mol Genet Genomic Med</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>1148</fpage>
            <page-range>1148-1156</page-range>
            <pub-id pub-id-type="pmid">30393977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32794.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ju</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Chemical screen identifies a geroprotective role of quercetin in premature aging.</article-title>
            <source>Protein Cell</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>417</fpage>
            <page-range>417-435</page-range>
            <pub-id pub-id-type="pmid">30069858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32794.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oshima</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maezawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yokote</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>RECQ helicase disease and related progeroid syndromes: RECQ2018 meeting.</article-title>
            <source>Mech Ageing Dev</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>173</volume>
            <fpage>80</fpage>
            <page-range>80-83</page-range>
            <pub-id pub-id-type="pmid">29752965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32794.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isaev</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Genrikhs</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Oborina</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Stelmashook</surname>
                <given-names>EV</given-names>
              </name>
            </person-group>
            <article-title>Accelerated aging and aging process in the brain.</article-title>
            <source>Rev Neurosci</source>
            <year>2018</year>
            <month>Mar</month>
            <day>28</day>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>233</fpage>
            <page-range>233-240</page-range>
            <pub-id pub-id-type="pmid">29150992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32794.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kusumesh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Ambastha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thakur</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Management of cataract in Werner syndrome.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>66</volume>
            <issue>9</issue>
            <fpage>1337</fpage>
            <page-range>1337-1339</page-range>
            <pub-id pub-id-type="pmid">30127165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32794.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Compagnucci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bertini</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The Potential of iPSCs for the Treatment of Premature Aging Disorders.</article-title>
            <source>Int J Mol Sci</source>
            <year>2017</year>
            <month>Nov</month>
            <day>07</day>
            <volume>18</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">29112121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32794.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dom&#x000ed;nguez-Gerpe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ara&#x000fa;jo-Vilar</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Prematurely aged children: molecular alterations leading to Hutchinson-Gilford progeria and Werner syndromes.</article-title>
            <source>Curr Aging Sci</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>202</fpage>
            <page-range>202-12</page-range>
            <pub-id pub-id-type="pmid">20021393</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
